Literature DB >> 8146198

The cellular proteins that bind specifically to the Epstein-Barr virus origin of plasmid DNA replication belong to a gene family.

S Zhang1, M Nonoyama.   

Abstract

This laboratory has previously reported that a tumor-promoting phorbol ester, phorbol 12-myristate 13-acetate ("12-O-tetradecanoylphorbol 13-acetate"), induces BJAB cells, a Burkitt lymphoma cell line, to express cellular proteins that bind to the origin of plasmid DNA replication (oriP) of Epstein-Barr virus. These oriP-binding proteins interfere with the EBV-encoded nuclear antigen EBNA-1, which binds to oriP in Raji cells. To further characterize these proteins, a lambda phage expression cDNA library made from phorbol ester-induced BJAB cells was screened for fusion proteins which bind to oriP. Two recombinant phages containing sequences encoding beta-galactosidase fusion proteins and designated lambda-OBP-1 and lambda-OBP-2 were identified. lambda-OBP-1 and lambda-OBP-2 contained 0.43 kbp and 0.61 kbp of BJAB cell cDNA, respectively, of which 395 bp were shared. Using lambda-OBP-1 as probe, two cDNAs of 1.4 kbp and 1.2 kbp, designated OBP-1 and OBP-2, respectively, were isolated. These cDNAs also shared the 395-bp sequence at the 3' end. With these cDNAs as probes, Northern blot analyses of mRNA from BJAB cells gave 1.4, 2.4, and 3.4-kb bands, but a Southern blot of human genomic DNA revealed one band. It is likely that the oriP-binding proteins were derived from spliced mRNA(s) of a gene family.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8146198      PMCID: PMC43467          DOI: 10.1073/pnas.91.7.2843

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line.

Authors:  T Lindahl; A Adams; G Bjursell; G W Bornkamm; C Kaschka-Dierich; U Jehn
Journal:  J Mol Biol       Date:  1976-04-15       Impact factor: 5.469

2.  Replication of the resident repressed Epstein-Barr virus genome during the early S phase (S-1 period) of nonproducer Raji cells.

Authors:  B Hampar; A Tanaka; M Nonoyama; J G Derge
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

3.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

4.  Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.

Authors:  T Nilsson; A Sjöblom; M G Masucci; L Rymo
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

5.  Identification of an Epstein-Barr virus nuclear antigen by fluoroimmunoelectrophoresis and radioimmunoelectrophoresis.

Authors:  B C Strnad; T C Schuster; R F Hopkins; R H Neubauer; H Rabin
Journal:  J Virol       Date:  1981-06       Impact factor: 5.103

6.  Analysis of single- and double-stranded nucleic acids on polyacrylamide and agarose gels by using glyoxal and acridine orange.

Authors:  G K McMaster; G G Carmichael
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

7.  Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose.

Authors:  H Aviv; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Yeast RNA polymerase II genes: isolation with antibody probes.

Authors:  R A Young; R W Davis
Journal:  Science       Date:  1983-11-18       Impact factor: 47.728

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  8 in total

1.  Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth.

Authors:  M S Kang; S C Hung; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

2.  Multiple regions within EBNA1 can link DNAs.

Authors:  D Mackey; T Middleton; B Sugden
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

3.  Cdc2-mediated phosphorylation of Kid controls its distribution to spindle and chromosomes.

Authors:  Miho Ohsugi; Noriko Tokai-Nishizumi; Katsuyuki Shiroguchi; Yoko Y Toyoshima; Jun-Ichiro Inoue; Tadashi Yamamoto
Journal:  EMBO J       Date:  2003-05-01       Impact factor: 11.598

4.  Analysis of cis-elements that facilitate extrachromosomal persistence of human papillomavirus genomes.

Authors:  Daraporn Pittayakhajonwut; Peter C Angeletti
Journal:  Virology       Date:  2008-02-14       Impact factor: 3.616

Review 5.  Gamma herpesviruses: pathogenesis of infection and cell signaling.

Authors:  J Rajcáni; M Kúdelová
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

6.  ComEA, a Bacillus subtilis integral membrane protein required for genetic transformation, is needed for both DNA binding and transport.

Authors:  G S Inamine; D Dubnau
Journal:  J Bacteriol       Date:  1995-06       Impact factor: 3.490

7.  A nuclear kinesin-like protein interacts with and stimulates the activity of the leucine-rich nuclear export signal of the human immunodeficiency virus type 1 rev protein.

Authors:  L K Venkatesh; T Gettemeier; G Chinnadurai
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

8.  Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1.

Authors:  S C Hung; M S Kang; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.